This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


Momotaro-Gene Inc.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2017/12/6
Profile

Delegates :
Hitoshi SHIOMI


Incorporated :
August  17 , 2007

Paid in Capital :
381 Million yen  

Employees :
7 人

Address :
OkayamaYanagimachi Bldg., 4F 1-12-1, Yanagimachi, Kita-ku, Okayama OKAYAMA
〒7000904

TEL/FAX :
+81-86-238-7848 / +81-86-238-7848

URL:
http://www.mt-gene.com/index_e.html

Attachment :

Mission/Background :
Momotaro-Gene Inc. is a biotech company spinning out of Okayama University. The company mission is to bridge technological seeds from academia to the industry or collaboration with the industry to launch new drug to the market. Our first technology is REIC/Dkk-3 gene therapy. This gene is isolated and cloned at Okayama University by Prof. Namba and his team. When he did the immortalized cell research, he found the expression of that specific gene very much reduced and named it REIC (Reduced Expression in Immortalized Cells). This gene is a tumor suppressor gene whose expression is reduced in most of the tumors.
Later, Prof. Kumon, former Chair of Urology Dept. there has led its clinical development and established Momotaro-Gene Inc., promoting the clinical study in Japan and clinical trial in the US both on prostate cancer to establish the POC of Ad-REIC gene therapy to solid tumor. We are now promoting clinical development for other indications such as liver cancer and malignant mesothelioma.

Technology & Business
Ad-REIC gene therapy has the promising anti-cancer effect with minimally invasive side effect (only temporary fever) by causing cancer specific apoptosis via ER stress and enhancing tumor immunological effect with REIC protein. Its POC for the first generation product was established by the Okayama University clinical study on the 26 prostate cancer patients. The ten-time high effective second generation product, Ad-SGE-REIC, also completed its Phase I study in the US with 12 patients with the same side effect and 10-time higher efficacy.
In Japan, Kyorin Pharmaceutical started Ad-SGE-REIC Phase I clinical trial for malignant mesothelioma in September, 2015. We have also started its Phase I clinical for liver cancer at Okayama University Hospital from July, 2017.
In the US, we have been doing its Phase IIa trial for early prostate cancer since July, 2016. Concurrently, we had a license deal with EPS Co.Ltd. for China right. We are promoting this three-polar-development, US, Japan, and China, scheme.
Products & Service
Products & Service Name
Stage
Outline
Milestone
Ad-SGE-REIC
Phase2
Ad-REIC gene therapy induces tumor specific apoptosis via ER stress and enhances cancer immunity via REIC protein
Entering Phase I/II trial for glioma
















Highlights
In the US, we entered into Ad-SGE-REIC Phase IIa trial for prostate cancer in July, 2016 and its malignant mesothelioma project was granted for Orphan Drug Status by FDA. In Japan, Kyorin Pharmaceutical started its malignant mesothelioma clinical trial in September, 2015. We have also started its Phase I clinical trial for liver cancer at Okayama University Hospital from July, 2017. In China, EPS China is aiming at IND submission on liver cancer as its first indication.
Hot news

Alliance strategy
We would like to have a license deal with the pharmaceutical or bio industry for the US/EU right of Ad-SGE-REIC

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.